Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Panel Matches Commissioner’s “Professional Judgment” Budget

Executive Summary

A supplemental appropriations/war funding measure containing $275 million for FDA cleared the Senate Appropriations Committee May 15

You may also be interested in...



More Money for FDA: Congress And White House Tussle Over Timing

Responding to congressional criticism that FDA is underfunded, the Bush administration amended its fiscal year 2009 budget request on June 9 to provide an extra $275 million to the agency

More Money for FDA: Congress And White House Tussle Over Timing

Responding to congressional criticism that FDA is underfunded, the Bush administration amended its fiscal year 2009 budget request on June 9 to provide an extra $275 million to the agency

FDA remains in the running for more money

An additional $275 million in appropriations for FDA are left intact as the Senate approves a fiscal 2008 war supplemental appropriations bill May 22. Funds for FDA include $100 million for drug, biologics and device safety and $40 million to enhance FDA science programs. The bill now returns to the House for a vote in the face of a threatened presidential veto (1"The Pink Sheet," May 19, 2008, p. 16). The Senate passed the measure on a 75-22 vote, a veto-proof majority

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel